- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02268656
Effect-site Concentration of Propofol for I-gel Insertion During Anesthesia Induction With a Single-dose Dexmedetomidine (D-pofol)
August 1, 2022 updated by: Youn Yi Jo, Gachon University Gil Medical Center
Preducted Effect-site Concentration of Propofol for I-gel Insertion During Anesthesia Induction
Before anethetic induction, infuse dexmedetomidine 0.5 mcg/kg for 2 minutes and after injection of lidocaine 30 mg, propofol infusion by using target controlled infusion (TCI) pump.
Effect site concentraion of propofol start from 5 and changes the concentration as previous response to i-gel insertion as up and down methods
Study Overview
Detailed Description
Before anethetic induction, infuse dexmedetomidine 0.5 mcg/kg for 2 minutes and after injection of lidocaine 30 mg, propofol infusion by using target controlled infusion (TCI) pump.
Effect site concentraion of propofol start from 5 and changes the concentration as previous response to i-gel insertion as up and down methods.
Failure of previous subjects are defined as difficulty to mouth open, severe nausea and couph and laryngeal spasm, and not loss of consciousness.
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 60 years (ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- ASA PS I-II, 20-60 yrs old
Exclusion Criteria:
- predicted difficulty airway, recent URI, BMI > 30kg/m2, reactive airway disease
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
OTHER: concentration of propofol in male
after infusion of dexmedetomidine dexmedetomidine 0.5 mcg/kgfor 2 min, infusion of propofol as using target controlled infusion pump.
Effect site concentration would be changed as the response to i-gel insertion as up and down method in male
|
First subjects start from effect site concentraion of 5ug/ml propofol, after insertion of i-gel, determine the next subjects' effect site concentraion would be increae or decrease 0.5 ug/ml as up and down method
Other Names:
|
|
OTHER: concentration of propofol in female
after infusion of dexmedetomidine dexmedetomidine 0.5 mcg/kgfor 2 min, infusion of propofol as using target controlled infusion pump.
Effect site concentration would be changed as the response to i-gel insertion as up and down method in female
|
First subjects start from effect site concentraion of 5ug/ml propofol, after insertion of i-gel, determine the next subjects' effect site concentraion would be increae or decrease 0.5 ug/ml as up and down method
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Concentration of Propofol
Time Frame: from i-gel insertion up to 5 min
|
effect site concentration of propofol
|
from i-gel insertion up to 5 min
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2014
Primary Completion (ACTUAL)
February 1, 2015
Study Completion (ACTUAL)
February 1, 2015
Study Registration Dates
First Submitted
October 9, 2014
First Submitted That Met QC Criteria
October 16, 2014
First Posted (ESTIMATE)
October 20, 2014
Study Record Updates
Last Update Posted (ACTUAL)
August 3, 2022
Last Update Submitted That Met QC Criteria
August 1, 2022
Last Verified
August 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GCIRB2014-153
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Igel
-
Aga Khan UniversityCompletedTraining Group, Sensitivity | IgelPakistan
-
Aristotle University Of ThessalonikiRecruitingPediatric Respiratory Diseases | Tracheal Stenosis | Apnea+Hypopnea | Cerebral Hypoxia | Igel | Tracheal DilatationGreece
Clinical Trials on propofol concentration
-
NestléCompletedStroke | DysphagiaBelgium, France
-
Shanxi Provincial Maternity and Children's HospitalUnknown
-
Topokine Therapeutics, Inc.Completed
-
Yale UniversityNational Institute on Drug Abuse (NIDA)Completed
-
Yonsei UniversityCompleted
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityNot yet recruiting
-
ALK-Abelló A/STerminated
-
Qilu Pharmaceutical Co., Ltd.Recruiting
-
MeiraGTx, LLCRecruitingGrade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid GlandsUnited States, United Kingdom, Canada
-
Osijek University HospitalCompletedHypoxia-Ischemia, Brain | Ischemia, Vertebral Artery | Artery Stenosis, CarotidCroatia